Details for Patent: 8,877,938

Which drugs does patent 8,877,938 protect, and when does it expire?

Patent 8,877,938 protects ENTRESTO and is included in one NDA.

Protection for ENTRESTO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has seventy-one patent family members in thirty-five countries.

Summary for Patent: 8,877,938

Title:	Compounds containing S-N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
Abstract:	A compound of an angiotensin receptor antagonist (ARB), a neutral endopeptidase inhibitor (NEPi) and one or more monovalent cations are useful for the treatment of hypertension and/or heart failure. ARB includes S--N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-v- aline in the anion form, NEPi includes (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester in the anion form and cation includes monovalent cations such as Na.sup.+. The compound includes trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propi- onate-(S)-3'-methyl-2'-(pentanoyl{2''-(tetrazol-5-ylate)biphenyl-4'-ylmeth- yl}amino)butyrate] hemipentahydrate.
Inventor(s):	Feng; Lili (Pine Brook, NJ), Godtfredsen; Sven Erik (Chatham, NJ), Hu; Bin (Green Brook, NJ), Liu; Yugang (Bridgewater, NJ), Karpinski; Piotr (Lincoln Park, NJ), Sutton; Paul Allen (Parsippany, NJ), Prashad; Mahavir (Montville, NJ), Girgis; Michael J. (Montville, NJ), Blacklock; Thomas J. (Clark, NJ)
Assignee:	Novartis Pharmaceuticals Corporation (East Hanover, NJ)
Application Number:	11/722,360
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,877,938
Patent Claim Types: see list of patent claims	Compound; Composition;

Drugs Protected by US Patent 8,877,938

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis Pharms Corp	ENTRESTO	sacubitril; valsartan	TABLET;ORAL	207620-001	Jul 7, 2015		RX	Yes	No					Y
Novartis Pharms Corp	ENTRESTO	sacubitril; valsartan	TABLET;ORAL	207620-002	Jul 7, 2015		RX	Yes	No					Y
Novartis Pharms Corp	ENTRESTO	sacubitril; valsartan	TABLET;ORAL	207620-003	Jul 7, 2015		RX	Yes	Yes					Y

Foreign Priority and PCT Information for Patent: 8,877,938

PCT Information
PCT Filed	November 08, 2006	PCT Application Number:	PCT/US2006/043710
PCT Publication Date:	May 18, 2007	PCT Publication Number:	WO2007/056546

International Family Members for US Patent 8,877,938

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	057882
Argentina	106613
Argentina	106614
Australia	2006311481
Brazil	122013025375